Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc Update on Duchenne Muscular Dystrophy Gene Therapy Program Conference Call Transcript

Mar 25, 2019 / 12:00PM GMT
Operator

Good morning, ladies and gentlemen, and welcome to the Sarepta Therapeutics microdystrophin gene therapy update conference call. As a reminder, today's program is being recorded.

I'll now turn the call over to Doug Ingram, President and CEO of Sarepta Therapeutics. Please go ahead.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Good morning, and thank you all for joining us for an update on the clinical data from our 4-patient Phase I Microdystrophin Gene Therapy Program. On this call, we may provide forward-looking statements. I would refer you all to our public filings for the risks and precautions associated with our forward-looking statements.

Now before I turn the discussion over to Dr. Louise Rodino-Klapac, let me put this update in context and explain why we are making it. As you all recall, at the World Muscle conference in Mendoza, Argentina in the fall of 2016, we provided an update on our 4-patient Phase I trial for gene therapy. We provided functional and biomarker results as a last date we had for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot